Graybug, LLC

Baltimore, MD 21231

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $650K
First Award Date 03/01/14
Most Recent Award Date 09/01/14

Key Personnel

Last Name Name Awards Contact
CAMPOCHIARO PETER A CAMPOCHIARO 2
CONNELLY SHEILA CONNELLY 1
YANG MING YANG 3
ZACK DONALD J. ZACK 1
WALSH MOLLY MCCARTHY WALSH 1

4 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 09/01/14 - 08/31/15

DESCRIPTION (provided by applicant): Glaucoma is a major cause of blindness, affecting over 70 million people worldwide. The development of glaucoma is most often associated with elevated intraocular pressure (IOP) which is induced by the dysfunction of the trabecular meshwork (TM) leading to inhibition of aqueous humor outflow. In most patients...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 09/01/14 - 08/31/15

DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) is the leading cause of blindness in older adults. The neovascular form of the disease (NVAMD) is primarily responsible for severe vision loss. Current NVAMD treatments involve repeated intraocular injections of biologics that neutralize vascular endothelial growth facto...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 05/01/14 - 04/30/15
PI: MING YANG

DESCRIPTION (provided by applicant): Glaucoma is a major cause of blindness, affecting over 70 million people worldwide. It is a neurodegenerative optic neuropathy in which vision loss results from the loss of retinal ganglion cells (RGC). Current therapies are all directed at lowering intraocular pressure (IOP), however, despite IOP lowering, R...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 03/01/14 - 02/28/15

ABSTRACT Age-related macular degeneration (AMD) is the leading cause of blindness in older adults with the neovascular form of the disease (NVAMD) mainly responsible for severe vision loss. Current NVAMD treatments involve repeated intraocular injections of biologics that neutralize vascular endothelial growth factor (VEGF), an important NV stim...